Venus Continues To Drive TAVR In China By Licensing In Australian Start-Up Tech
Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.
You may also be interested in...
Israel-based Cardiovalve is developing a transcatheter valve replacement system to treat mitral and tricuspid valve regurgitation.
Venus Medtech, the Chinese transcatheter aortic valve technology specialist, has made its second international acquisition as it pursues its strategy for global expansion in the TAVR market.
The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.